KYMR
Kymera Therapeutics Inc
$
40.730
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
41.810
Open
40.380
VWAP
40.33
Vol
831.58K
Mkt Cap
2.91B
Low
39.7131
Amount
33.54M
EV/EBITDA(TTM)
--
Total Shares
61.36M
EV
2.19B
EV/OCF(TTM)
--
P/S(TTM)
70.65
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
12.10M
-45.25%
-1.052
+28.25%
16.60M
+124.49%
-0.958
+7.65%
25.08M
+570.45%
-0.837
+2.02%
Estimates Revision
The market is revising Upward the revenue expectations for Kymera Therapeutics, Inc. (KYMR) for FY2025, with the revenue forecasts being adjusted by 14.33% over the past three months. During the same period, the stock price has changed by 30.80%.
Revenue Estimates for FY2025
Revise Upward
+14.33%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-4.38%
In Past 3 Month
Stock Price
Go Up
+30.80%
In Past 3 Month
17 Analyst Rating
50.58% Upside
Wall Street analysts forecast KYMR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KYMR is 61.33 USD with a low forecast of 53.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
0 Hold
0 Sell
Strong Buy
50.58% Upside
Current: 40.730
Low
53.00
Averages
61.33
High
70.00
50.58% Upside
Current: 40.730
Low
53.00
Averages
61.33
High
70.00
B. Riley
Mayank Mamtani
Buy
maintain
$60
2025-07-30
Reason
B. Riley
Mayank Mamtani
Price Target
$60
2025-07-30
maintain
Buy
Reason
B. Riley analyst Mayank Mamtani kept a Buy rating on Kymera Therapeutics with a $60 price target following a transfer of coverage. The firm says investor enthusiasm appears to be building for KT-621's Phase 1b atopic dermatitis patient data update in Q4. Riley is "encouraged" by the "impressive" safety profile already demonstrated at high doses.
Goldman Sachs
Andrea Newkirk
initiated
2025-07-15
Reason
Goldman Sachs
Andrea Newkirk
Price Target
2025-07-15
initiated
Reason
Goldman Sachs analyst Andrea Newkirk initiated coverage of Kymera Therapeutics with an Early-Stage Biotech rating. The firm says Kymera is an early, clinical-stage biopharmaceutical company.
BofA
Buy
maintain
$51 -> $54
2025-06-29
Reason
BofA
Price Target
$51 -> $54
2025-06-29
maintain
Buy
Reason
BofA raised the firm's price target on Kymera Therapeutics (KYMR) to $54 from $51 and keeps a Buy rating on the shares. The company announced that its partner Sanofi (SNY) decided to advance KT-485, an oral IRAK4 degrader, into the clinic and discontinue development of KT-474, the analyst tells investors in a research note. The firm says that while the KT-474 update will set back the program by several years, the update reinforces Kymera and Sanofi's commitment to developing the best possible IRAK4 degrader. It remains "encouraged" by Kymera's "strong" business development capabilities to establish collaborations with large pharma for several assets in its pipeline.
Oppenheimer
Jeff Jones
Outperform
maintain
$56 -> $53
2025-06-27
Reason
Oppenheimer
Jeff Jones
Price Target
$56 -> $53
2025-06-27
maintain
Outperform
Reason
Oppenheimer analyst Jeff Jones lowered the firm's price target on Kymera Therapeutics (KYMR) to $53 from $56 and keeps an Outperform rating on the shares. Kymera announced a "speed bump" in its Sanofi (SNY) partnership on IRAK4, with Sanofi abandoning clinical-stage KT-474 in favor of an earlier stage candidate KT-485, the analyst tells investors in a research note. While this is a delay to what an important asset, it has a limited impact to the firm's model, with its focus remaining on STAT6 targeting KT-621, Oppenheimer says.
Wells Fargo
Overweight
downgrade
$57 -> $53
2025-06-26
Reason
Wells Fargo
Price Target
$57 -> $53
2025-06-26
downgrade
Overweight
Reason
Wells Fargo lowered the firm's price target on Kymera Therapeutics (KYMR) to $53 from $57 and keeps an Overweight rating on the shares. Sanofi's (SNY) shifting from KT-474 to KT-485 is a modest disappointment, but will mostly just push timelines for a program that Kymera receives only economics for, the analyst tells investors in a research note. The firm sees limited downside and no risk to KT-621.
H.C. Wainwright
Andrew Fein
Buy
maintain
$54 -> $60
2025-06-26
Reason
H.C. Wainwright
Andrew Fein
Price Target
$54 -> $60
2025-06-26
maintain
Buy
Reason
H.C. Wainwright analyst Andrew Fein raised the firm's price target on Kymera Therapeutics (KYMR) to $60 from $54 and keeps a Buy rating on the shares. The company announced that Sanofi (SNY) had decided to discontinue further development of KT-474, instead choosing to pursue KT-485, Kymera's next generation oral IRAK4 degrade, the analyst tells investors in a research note. The firm says this pushes back the timeline in the competitive atopic dermatitis and hidradenitis suppurativa markets. H.C. Wainwright finds it strategically wise to focus on a next-generation IRAK4 degrader with superior efficacy and safety. For Kymera, the STAT6 program might be most significant as a near-term key value driver, with the Phase 1b data expected in Q4, adds the firm.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Kymera Therapeutics Inc (KYMR.O) is -9.38, compared to its 5-year average forward P/E of -18.21. For a more detailed relative valuation and DCF analysis to assess Kymera Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-18.21
Current PE
-9.38
Overvalued PE
1.13
Undervalued PE
-37.54
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-17.13
Current EV/EBITDA
-5.83
Overvalued EV/EBITDA
2.12
Undervalued EV/EBITDA
-36.39
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Overvalued
5Y Average PS
31.61
Current PS
50.78
Overvalued PS
45.01
Undervalued PS
18.22
Financials
Annual
Quarterly
FY2025Q2
YoY :
-55.26%
11.48M
Total Revenue
FY2025Q2
YoY :
+66.04%
-84.56M
Operating Profit
FY2025Q2
YoY :
+82.15%
-76.61M
Net Income after Tax
FY2025Q2
YoY :
+63.79%
-0.95
EPS - Diluted
FY2025Q2
YoY :
+27.20%
-60.58M
Free Cash Flow
FY2025Q2
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q2
-565.67
FCF Margin - %
FY2025Q2
YoY :
+307.12%
-667.60
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 3617.7% over the last month.
Sold
0-3
Months
2.8M
USD
5
3-6
Months
574.8K
USD
5
6-9
Months
253.2K
USD
2
0-12
Months
651.8K
USD
1
Bought
0-3
2
42.8M
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
117.0K
Volume
1
6-9
Months
338.9K
Volume
3
0-12
Months
454.0K
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
1
1.3M
Volume
Months
6-9
3
1.4M
Volume
Months
0-12
1
1.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 3617.7% over the last month.
Sold
0-3
Months
2.8M
USD
5
3-6
Months
574.8K
USD
5
6-9
Months
253.2K
USD
2
0-12
Months
651.8K
USD
1
Bought
0-3
2
42.8M
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
KYMR News & Events
Events Timeline
2025-08-11 (ET)
2025-08-11
07:06:20
Kymera Therapeutics sees cash runway into 2H28
2025-08-11
07:05:52
Kymera Therapeutics reports Q2 EPS (95c), consensus (80c)
2025-07-11 (ET)
2025-07-11
17:13:55
Gilead estimates Q2 acquired IPR&D expenses of $61M
Sign Up For More Events
Sign Up For More Events
News
9.5
08-11NASDAQ.COMPinnedKymera Revenue Drops 55 Percent in Q2
3.0
08-08NASDAQ.COMPre-Market Earnings Report for August 11, 2025 : B, B, FNV, MNDY, ROIV, LEGN, TDS, USM, KYMR, RUM, DOLE, SPHR
3.0
08-08Yahoo FinanceEarnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q2 2025 Result
Sign Up For More News
People Also Watch
ABR
Arbor Realty Trust Inc
12.070
USD
+0.42%
ENOV
Enovis Corp
29.590
USD
+2.92%
DRVN
Driven Brands Holdings Inc
17.290
USD
+2.92%
TTMI
TTM Technologies Inc
44.960
USD
-3.58%
LIVN
LivaNova PLC
53.060
USD
+4.78%
AZZ
AZZ Inc
116.550
USD
+2.62%
PLTK
Playtika Holding Corp
3.780
USD
-0.79%
FLNC
Fluence Energy Inc
7.550
USD
+2.44%
ATS
ATS Corp
28.960
USD
+1.08%
STNE
StoneCo Ltd
15.700
USD
+3.36%
FAQ
What is Kymera Therapeutics Inc (KYMR) stock price today?
The current price of KYMR is 40.73 USD — it has increased 2.16 % in the last trading day.
What is Kymera Therapeutics Inc (KYMR)'s business?
What is the price predicton of KYMR Stock?
What is Kymera Therapeutics Inc (KYMR)'s revenue for the last quarter?
What is Kymera Therapeutics Inc (KYMR)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Kymera Therapeutics Inc (KYMR)'s fundamentals?
How many employees does Kymera Therapeutics Inc (KYMR). have?